Hoppnic

Hoppnic operates at the intersection of medical devices, assistive technology, hardware, and 3D manufacturing. Its stated focus is personalized upper-limb prostheses, with BioHopp models spanning sensor-controlled and mechanical approaches for different amputation levels. The portfolio includes the sensor-controlled B2, B3, and B4, alongside the mechanically operated M1 and M2. This breadth within upper-limb prosthetics, paired with an installment financing program and consultation options, distinguishes the company’s described offering from a device-only proposition. Its categories indicate a small, specialized assistive-device focus rather than a broad healthcare platform. Accordingly, Hoppnic can be characterized by its product scope and accessibility emphasis, but not ranked against specific competitors on the evidence available.

Hoppnic was founded in 2024 and is described as an active, privately held company based in Lima, Peru. Its listed portfolio covers five upper-limb prosthesis models: three sensor-controlled BioHopp devices and two mechanically controlled models. It also offers a prosthesis financing program, suggesting that the company’s approach extends beyond device design to payment accessibility. The range of models for different amputation levels represents the clearest indication of product breadth, while consultation options provide an additional user-facing service. There are no disclosed funding rounds, funding totals, valuation figures, employee counts, hiring updates, or dated product launches with which to measure commercial acceleration or identify a specific growth inflection point. The available facts therefore support a description of an early-stage company building out a specialized product and access offering, not a conclusion about revenue, scale, or growth rate. Future assessment would benefit from verified information on clinical adoption, production capacity, distribution, regulatory status, financing, and customer outcomes.